Joshua Veatch is an Oncology physician affiliated with Fred Hutch Cancer Center. OpenAlex indexes 59 publications with 1,530 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1100 Fairview Ave N # D5-100
Seattle, WA 981094433
Telephone
206-618-5181Registry record last updated 5 Aug 2013.
Clinical trials
- Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Sponsor: Fred Hutchinson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
50%Corticosteroid50%Hydrocortisone100%Part D<11 patientsMetabolism & gastrointestinal
50%Corticosteroid50%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Targeting the tumor microenvironment with engineered CD4+ T cells
Fred Hutchinson Cancer Center
FY2026$693,882R37CA292663 - Targeting the tumor microenvironment with engineered CD4+ T cells
Fred Hutchinson Cancer Center
FY2025$693,880R37CA292663 - Targeting the tumor microenvironment with engineered CD4+ T cells
Fred Hutchinson Cancer Center
FY2024$693,880R37CA292663
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Stanley Riddell, MD
Fred Hutch Cancer Center
Sunil Hingorani, MD, PhD
Fred Hutch Cancer Center
Paul Nghiem
Fred Hutch Cancer Center
Soheil Meshinchi, MD, PhD
Fred Hutch Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”